Corsi and DiMeglio are both responsible for leading marketing and growth strategies for their distinct companies. Corsi is ...

The general manager of the Bila Solar unit in Indianapolis, said legislation could impede plans to expand the company’s solar ...

President Trump has threatened to impose pharma tariffs to encourage investment in U.S. manufacturing, but experts say there could be unintended consequences.

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

The plane maker is betting that demand for aircraft will continue to fuel growth in coming years. The systems will be jointly developed and produced by the two companies, with suppliers and industrial ...

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for ...